Insulet (PODD) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Insulet Corporation (PODD) PT Lowered to $310 at BTIG
February 24, 2022 12:59 PM ESTBTIG analyst Marie Thibault lowered the price target on Insulet Corporation (NASDAQ: PODD) to $310.00 (from $320.00) while maintaining a Buy rating.
The analyst commented, "Insulet reported Q4 revenue of $307.7M (+25% y/y rep, +25.7% y/y cc), beating consensus estimates of $299.3M and our $303.2M forecast. U.S. Omnipod revenue was relatively in line with our expectations but OUS headwinds, including ongoing pressures from competitive AID systems and an estimated $5M... More
